Yousheng Mao

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Knee Osteoarthritis

Medical Education

Childhood Cancer

Top Venues

Journal of gastroenterology and hepatology

Postgraduate medical journal

Journal of immunology research

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Hang Yi, Yang Cao, Qihao Leng, Yan Wang, Guochao Zhang, Yousheng Mao
The impact of open access on citations, Pageviews, and downloads: a scientometric analysis in Postgraduate Medical Journal. Postgraduate medical journal 100 (1187) (2024)
Hang Yi, Yang Cao, Qihao Leng, Yan Wang, Guochao Zhang, Yousheng Mao
The impact of open access on citations, Pageviews, and downloads: a scientometric analysis in Postgraduate Medical Journal. Postgraduate medical journal (2024)
Hang Yi, Yiwen Lin, Xuefei Wang, Yousheng Mao
Pan-cancer analysis of TRPV2 identifies its potential role as a prognostic and immunologic biomarker in oesophageal cancer. British journal of cancer (2023)
Feng Li, Suokai Zhai, Li Fu, Lin Yang, Yousheng Mao
Nomograms for intraoperative prediction of lymph node metastasis in clinical stage IA lung adenocarcinoma. Cancer medicine (2023)
Hang Yi, Shuofeng Li, Yiwen Lin, Feng Li, Shuaibo Wang, Donghui Jin, Zhuoheng Lv, Li Fu, Yousheng Mao
Risk and Prognosis of Secondary Thoracic Cancers after Radiation Therapy for Esophageal Cancer. Journal of gastroenterology and hepatology (2023)
Hang Yi, Shuofeng Li, Yiwen Lin, Feng Li, Shuaibo Wang, Donghui Jin, Zhuoheng Lv, Li Fu, Yousheng Mao
Risk and prognosis of secondary thoracic cancers after radiation therapy for esophageal cancer. Journal of gastroenterology and hepatology (2023)
Hang Yi, Yiwen Lin, Yutong Li, Yeqi Guo, Ligong Yuan, Yousheng Mao
Pan-Cancer Analysis of B4GALNT1 as a Potential Prognostic and Immunological Biomarker. Journal of immunology research 2022 (2022)
Feng Li, Yue Zhao, Ligong Yuan, Shuaibo Wang, Yousheng Mao
Oncologic outcomes of segmentectomy vs lobectomy in pathologic stage IA (≤2 cm) invasive lung adenocarcinoma: A population-based study. Journal of surgical oncology 121 (7) (2020)